An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)
An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)
Inclusion Criteria:
Exclusion Criteria:
Stanford, California 94305, United States
New Hyde Park, New York 11042, United States
Pittsburgh, Pennsylvania 15232, United States
Walla Walla, Washington 99362, United States
Fitzroy Melbourne, Victoria 3065, Australia
Hangzhou, Zhejiang 310003, China
Novara, 28100, Italy
Wellington South, Wellington Region 6021, New Zealand
Christchurch, 8011, New Zealand
Brzozów, Podkarpackie Voivodeship 36-200, Poland
Gdansk, Pomeranian Voivodeship 80-952, Poland
Chorzów, Silesian Voivodeship 41-500, Poland
Ryazan, Ryazan Oblast 390039, Russia
Majadahonda, Madrid 28222, Spain
Izmir, 35040, Turkey (Türkiye)
Vinnytsia, Vinnytsia Oblast 21018, Ukraine
Cherkasy, 18009, Ukraine
Dnipro, 49102, Ukraine
Lviv, 79044, Ukraine
Poole, Dorset BH15 2JB, United Kingdom
Southampton, Hampshire SO16 6YD, United Kingdom
Nottingham, Nottinghamshire NG5 1PB, United Kingdom
Oxford, Oxfordshire OX3 9DU, United Kingdom